BCL2 and cancer: Consistent with our data, 9‐ING‐41, a small molecule inhibitor of GSK‐3β, has demonstrated anti‐tumor activity in patient‐derived xenograft mice (PDX) of various human cancers including PDAC by inhibiting the NF‐κB target genes such as BCL‐2 [16].